Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for GFH375 (VS-7375) in KRAS G12D Advanced Solid Tumors. The expected timing is based on the latest available company guidance and may change.
VS-7375-101 trial. Collab w/ GenFleet Therapeutics (China). 7/12/24- First patient dosed in China. 4/23/25- US IND cleared. 6/24/25- First patient dosed in US trial. 10/23/25– Reported preliminary data w/ tumor reduction. Interim update planned H1‗2026. 11/04/25:- 400/600mg doses cleared without DLTs; 4/5 patients showed tumor reductions. Interim update and RP2D expansions planned H1 2026. 12/29/25:- Program prioritized; Ph1/2 VS-7375 showed 69% ORR in KRAS G12D NSCLC; interim update planned H1 2026. 03/04/26:- VS-7375-101 cleared 900 mg; early data and CRC combo RP2D/expansion expected 1H 2026; further enrollments mid-2026. 03/18/26:- VS-7375 has FDA Fast Track for KRAS G12D PDAC; AACR 2026 preclinical data Apr 20-22. 05/07/26:- TARGET-D 101 early data expected H1 2026; mature data update planned H2 2026; multiple Phase 2 trials initiating mid-2026. 06/03/26:- TARGET-D 101 now testing 1200 mg and cetuximab combo. Early data H1 2026; mature data H2 2026. 06/16/26:- Investor call June 23, 2026 to present updated preliminary TARGET-D 101 data. TARGET-D 101 evaluating 1200 mg monotherapy and combos incl cetuximab, gem/nab-paclitaxel, or chemo-immunotherapy. 06/23/26:- TARGET-D 101 prelim data positive; enroll end Jun 2026; update H2 2026; Ph3 start H1 2027. 08/06/26:- TARGET-D 101 complete; 1200mg cleared. Data October 2026. Ph2 ends 2026. Ph3 H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.